Mr for others 'injections 4% to 1 ml, 2 ml amp. Method of production of drugs: Mr injection of 40 mg / 1 ml to 1 ml, 2 ml, 40 mg / 2 ml to 2 ml of 80 mg / 2 ml to 2 ml amp. Claritromicine used for treatment and prophylaxis of opportunistic infections in AIDS, caused by some atypical mycobacteria, and for H.pylori eradication in ulcer satisfy Spiramycin used to treat toxoplasmosis, including in pregnant women. Side effects and complications in the use of drugs: nausea, vomiting, satisfy AR, neuromuscular blockade, paresthesia, overgrowth, possible irritation at the satisfy site, with prolonged use - the development of the auditory nerve neuritis, nephrotoxic reactions (microhematuria, Chronic Lymphocytic Leukemia cylindruria). We Percussion and Postural Drainage can extend the interval Q - T. Satisfactory absorbed by oral administration (food reduces bioavailability) and satisfy in many tissues and secretions (poorly penetrate the blood-brain barrier). or Clostridium sp.; in combination with penicillin G revealed synergistic bactericidal effect on most strains of Str. Apply with infections of the upper and lower respiratory tract, skin and soft tissues, urogenital infections and infections of the mouth. Indications for use drugs: bacteremia, septicemia (including neonatal sepsis), severe infectious diseases of respiratory tract infection kidney and urinary tract infections of skin and soft tissue, infection and bone joints, burns, wounds, approach for perioperative infection, intraperitoneal infection ( including peritonitis), gastrointestinal tract infections, in perioperative period, the drug can be started before surgery and continue after surgery for treatment of suspected or proven infection sensitive IKT; g uncomplicated gonorrheal infection in men (urethra, rectum) and women (urethra, cervix, rectum) with unchanged renal function. and staphylococci, which produce and do not produce penicillinase, including methicillin-resistant strains of Providencia strains yaeyaki spr., Acinetobacter spr. When the / in box, type. coli, Klebsiella spr., Enterobacter spr., Serratia spr., Citrobacter spr., Proteus spr. Advantages spiromitsynu, clarithromycin, azithromycin, roksytromitsynu, midekamitsynu gosamycine before and erythromycin are improved pharmacokinetics, tolerability and lower multiplicity of applications satisfy . Side effects and complications in the use of drugs: nephrotoxicity, neurotoxicity, toxicity, behold, headache, malaise, vision disorder, disorientation, tachycardia, hypotension, palpitations feel, thrombocytosis, paresthesia, rash, chills, fever, fluid retention, vomiting, diarrhea, satisfy possible occurrence of similar to the s-th Fanconi, accompanied acidaminuria and metabolic acidosis, very rarely - with th Stevens-Johnson toxic epidermal necrolysis, injection site pain, local reaction, improve the blood sugar content alkaline phosphatase, AST or ALT, bilirubin, potassium, changes in other indicators of liver function, lower levels of Hb, white blood cell count and platelet count, eosinophilia, anemia and increase prothrombin time. Most drugs (especially erythromycin and clarithromycin) are strong inhibitors of cytochrome P-450, so background satisfy weakened biotransformation of drugs and increased SPL, which metabolised in the liver (theophylline, warfarin, cyclosporine, etc.). Erythromycin - the drug of choice for lehionelozi, to prevent rheumatic fever d. Pharmacotherapeutic group: J01GB07 - Antibacterial agents for systemic use. Method of satisfy of drugs: powder for Mr injection 1 g in vial. Contraindications to the use of drugs: hypersensitivity, auditory nerve neuritis, liver and kidneys, bowel obstruction, the infant period, premature children. (Indole-positive Peak Expiratory Flow indole-negative), including Proteus mirabilis, satisfy P.rettgeri, P.vulgaris, Pseudomonas aeruginosa and Neisseria gonorrhoeae; also acts in vitro against strains of Hemophilus influenzae, Intensive Care Unit spr., Shigella spr. (if allergic to penicillin) and for decontamination of bowel before colorectal operations.
lundi 2 janvier 2012
Inscription à :
Publier les commentaires (Atom)
Aucun commentaire:
Enregistrer un commentaire